BenevolentAI vs SigTuple

Neither company has publicly disclosed a valuation, making a definitive size comparison difficult. BenevolentAI employs 100-500 people, while SigTuple has 100-500 employees.

BenevolentAI has raised more in total funding at $292M, compared to SigTuple's $20M — a gap of $272M.

BenevolentAI holds the higher Awaira Score at 62/100, compared to SigTuple's 60/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 2-point gap that reflects meaningful differences in scale or traction.

BenevolentAI was founded by Joanna Shields in 2013. SigTuple was founded by Rohit Kumar Pandey in 2015. Visit each company's profile on Awaira for a full founder biography.

BenevolentAI: BenevolentAI applies machine learning to drug discovery, using knowledge graph technology and predictive AI models to identify novel drug candidates and repurpose existing compounds for new therapeutic applications. The London-based company has built a proprietary biomedical knowledge graph containing billions of data points extracted from scientific literature, clinical trial data, and genomic databases, which feeds its target identification and molecule generation pipelines.\n\nThe company went public on Euronext Amsterdam in 2022 via a SPAC merger with Odyssey Acquisition, having previously raised approximately $292 million in private funding from backers including SoftBank, Woodford Investment Management, and Mayfair Equity Partners. BenevolentAI has clinical-stage programs in atopic dermatitis and amyotrophic lateral sclerosis, developed from AI-generated hypotheses that were subsequently validated in wet lab experiments and progressed into human trials.\n\nBenevolentAI operates in the AI drug discovery sector alongside Recursion Pharmaceuticals, Exscientia, and Insilico Medicine. The company faces the inherent challenge of all computational drug discovery platforms in demonstrating that AI-generated candidates can survive clinical attrition at higher rates than traditionally discovered drugs. The platform is considered one of the more mature AI drug discovery systems in Europe, with the longest track record of moving AI-generated hypotheses into clinical development. SigTuple: SigTuple develops AI-powered automated pathology solutions that digitize and analyze microscopy slides for blood, urine, sputum, and semen samples, enabling high-throughput diagnostic testing without the constant presence of trained pathologists. The company's AI-Minth platform uses robotic sample preparation, high-resolution imaging, and deep learning analysis to deliver diagnostic-grade results.\n\nThe company raised approximately $20M in Series B funding and has deployed its automated microscopy systems at diagnostic labs, hospitals, and blood banks across India, processing millions of diagnostic samples. SigTuple has received regulatory approvals for its diagnostic AI products and has established partnerships with major diagnostic laboratory chains.\n\nIndia faces a severe shortage of qualified pathologists relative to population, creating an acute need for AI-assisted diagnostic automation. SigTuple's approach of combining hardware, robotics, and AI in an integrated system addresses the complete diagnostic workflow rather than just the software layer, creating higher deployment barriers but also higher switching costs and stronger network effects from accumulated diagnostic data.

BenevolentAI was founded first in 2013, giving it 2 years of additional market experience. SigTuple was founded later in 2015. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

Both BenevolentAI and SigTuple report similar employee counts of approximately 100-500. Team size is often a proxy for operational scale, though lean AI companies can punch well above their headcount.

Yes, BenevolentAI and SigTuple are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.